ARKG ARK Genomic Revolution ETF
- 24.890
- +0.390+1.59%
Why Intellia Therapeutics Shares Are Trading Higher Monday
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is moving higher Monday after the company announced long-term data from its Phase 1 Study of NTLA-2002.The Details: Intellia's NTLA-2002 is an experimen
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Intellia Rallies on Phase 1 Data for CRISPR-based HAE Therapy
Market-Moving News for June 3rd
GME: 103% | 'Roaring Kitty' Reveals Massive GME Position On Reddit, Including $65M Call Options: Is He Bringing 'Courage' Back To Wall Street?BPTH: 81% | Bio-Path Presented Interim Results From Phase
Moderna And Merck Announced The First Presentation Of Results From A Planned Analysis From The Phase 2B KEYNOTE-942/mRNA-4157-P201 Study Of MRNA-4157 (V940) Plus Keytruda In Patients With Resected High-risk Melanoma Following Complete Resection (N=157)
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable i
Breaking Down Moderna: 7 Analysts Share Their Views
During the last three months, 7 analysts shared their evaluations of Moderna (NASDAQ:MRNA), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, shed
Moderna Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 — Needham Reiterates → Hold 05/14/2024 -16.29% Evercore ISI Group → $120 Initiates Coverage On
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 59.7% Needham $60 → $60 Reiterates Buy → Buy 05/08/2024 118.26% Wells Fargo $85 → $82 Maintains
Stocks Most Shunned by Hedge Funds and Mutual Funds
Intellia Therapeutics Announced Single Dose Of Ntla-2002 Led To A 98% Mean Reduction In Monthly Hereditary Angioedema Attack Rate, With An Average Follow-up Of Over 20 Months Across All Patients
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phas
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Friday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE).Donidalorsen had a favor
Decoding 6 Analyst Evaluations For CareDx
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months.The table below summarizes their recent ratings, s
Moderna's RSV vaccine received FDA approval as the first RNA vaccine other than COVID-19
The US Food and Drug Administration (FDA) approved Moderna's respiratory syncytial virus (RSV) vaccine on Friday for adults 60 and older. This is the company's second product to enter the US market. Analysts believe this approval is a win for Moderna, and the company urgently needs a new revenue stream as demand for its only commercial product, the COVID-19 vaccine, is falling sharply. According to information, Moderna's approval of the RSV vaccine is based on the results of advanced trials targeting the elderly, who are more likely to have severe RSV cases. According to US Disease Control
CareDx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 — HC Wainwright & Co. Reiterates → Neutral 05/17/2024 62.72% Craig-Hallum $15 → $22 Maintains
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc's (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic
Ionis Hereditary Angioedema Therapy Succeeds in Late-stage Trials
US Market Movers & Shakers in May: VFS, FSLR, MSTR and More
VinFast has seen a surge of 90.23% in May, while First Solar and MicroStrategy rose by 56.99% and 44.69% respectively.
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhood Markets Inc (NASDAQ:HOOD) shares. This move comes as Robinhood launches
EU Approves Biogen Treatment for Genetic Form of ALS